Levofloxacin

Generic Name: Levofloxacin

Brand Names: Levaquin, Quinsair

Drug Type: Small Molecule

Chemical Formula: C_₁₈H_₂₀FN_₃O_₄

CAS Number: 100986-85-4

Unique Ingredient Identifier: RIX4E89Y14

Background: Levofloxacin is a fluoroquinolone antibiotic and the optical S-(-) isomer of racemic ofloxacin. It reportedly carries 8 to 128-fold more activity against both gram-negative and gram-positive bacteria compared to R-(+)-ofloxacin and remains stereochemically stable following administration (i.e. it does not invert to the inactive isomer). Levofloxacin, along w...

Indication: In oral and intravenous formulations, levofloxacin is indicated in adults for the treatment of various infections caused by susceptible bacteria, including infections of the upper respiratory tract, lower respiratory tract, skin, skin structures, urinary tract, and prostate. The oral formulation is also indicated in both adults and children 6 months of age a...

Associated Conditions: Abscesses caused by susceptible bacteria, Acute Bacterial Exacerbation of Chronic Bronchitis (ABECB) caused by susceptible bacteria, Acute Pyelonephritis caused by Infection Due to Escherichia Coli, Bacterial Conjunctivitis caused by susceptible bacteria, Cellulitis caused by susceptible bacteria, Community Acquired Pneumonia (CAP) caused by susceptible bacteria, Furuncle caused by susceptible bacteria, Impetigo caused by susceptible bacteria, Inhalational Anthrax, Nosocomial Pneumonia caused by Pseudomonas Infections, Nosocomial Pneumonia caused by susceptible bacteria, Plague caused by Yersinia pestis, Pyoderma caused by susceptible bacteria, Wound Infections caused by susceptible bacteria, Acute bacterial sinusitis caused by susceptible bacteria, Chronic Bacterial prostatitis caused by susceptible bacteria, Chronic Pseudomonas Infections, Complicated Urinary Tract Infection caused by susceptible bacteria, Complicated skin and skin-structure infections caused by susceptible bacteria, Uncomplicated Urinary Tract Infection caused by susceptible bacteria, Uncomplicated skin and skin-structure infections caused by susceptible bacteria

Associated Therapies: -

Clinical Trials

Phase II Investigation of Antimycobacterial Therapy on Progressive, Pulmonary Sarcoidosis

Phase 2

Completed

Conditions: Sarcoidosis; Antimycobacterial Therapy

Interventions: Drug: Placebo
Drug: Levofloxacin
Drug: Ethambutol
Drug: Azithromycin
Drug: Rifampin

First Posted Date: 2013-12-31

Last Posted Date: 2020-07-09

Lead Sponsor: Vanderbilt University

Target Recruit Count: 97

Registration Number: NCT02024555

Locations: 🇺🇸
Ohio State University, Columbus, Ohio, United States
🇺🇸
Cleveland Clinic, Cleveland, Ohio, United States
🇺🇸
Vanderbilt University School of Medicine, Nashville, Tennessee, United States

and more 3 locations

Pharmacokinetics of Levofloxacin in Intensive Care Unit

Phase 4

Completed

Conditions: Intensive Care Unit Syndrome
Community-acquired Pneumonia

Interventions: Drug: Levofloxacin

First Posted Date: 2013-12-23

Last Posted Date: 2015-03-05

Lead Sponsor: University Hospital, Toulouse

Target Recruit Count: 52

Registration Number: NCT02018081

Locations: 🇫🇷
University Hospital Toulouse, Toulouse, France

Efficacy and Safety Study of Eravacycline Compared With Levofloxacin in Complicated Urinary Tract Infections

Phase 3

Completed

Conditions: cUTI

Interventions: Drug: Eravacycline
Drug: Levofloxacin

First Posted Date: 2013-11-08

Last Posted Date: 2022-01-11

Lead Sponsor: Tetraphase Pharmaceuticals, Inc.

Target Recruit Count: 908

Registration Number: NCT01978938

Locations: 🇺🇸
Harbor-UCLA Medical Center, Torrance, California, United States
🇺🇸
Columbus Regional Research Institute, Columbus, Ohio, United States
🇨🇿
Thomayer Hospital, Department of Urology, Prague, Czechia

and more 96 locations

Efficacy and Safety of Levofloxacin for the Treatment of MDR-TB

Phase 2

Completed

Conditions: Tuberculosis, Multidrug-Resistant

Interventions: Drug: Levofloxacin
Drug: Optimized background regimen (OBR)

First Posted Date: 2013-08-07

Last Posted Date: 2023-05-24

Lead Sponsor: Boston University

Target Recruit Count: 111

Registration Number: NCT01918397

Locations: 🇵🇪
Partners in Health, Lima, Peru
🇵🇪
University of Cayetana Heredia, Lima, Peru
🇿🇦
Stellenbosch University, Cape Town, South Africa

Efficacy of a Short-term Sequential Therapy in Non-complicated Catheter Related Bacteremia by Methicillin- Susceptible S.Aureus.

Phase 3

Terminated

Conditions: Staphylococcus

Interventions: Drug: Cloxacilin
Drug: Cloxacillin
Drug: Levofloxacin

First Posted Date: 2013-06-11

Last Posted Date: 2015-08-07

Lead Sponsor: Fundación Pública Andaluza Progreso y Salud

Target Recruit Count: 1

Registration Number: NCT01875263

Locations: 🇪🇸
Hospital Universitario Reina Sofía, Córdoba, Spain
🇪🇸
Hospital de Antequera, Málaga, Spain
🇪🇸
Hospital Universitario Virgen de la Victoria, Málaga, Spain

and more 8 locations

"Efficacy and Safety of Levofloxacin vs Isoniazid in Latent Tuberculosis Infection in Liver Transplant Patients".

Phase 3

Terminated

Conditions: Latent Tuberculosis Infection
Infection in Solid Organ Transplant Recipients

Interventions: Drug: Isoniazid
Drug: Levofloxacin

First Posted Date: 2013-01-04

Last Posted Date: 2014-08-06

Lead Sponsor: Fundación Pública Andaluza para la gestión de la Investigación en Sevilla

Target Recruit Count: 68

Registration Number: NCT01761201

Locations: 🇪🇸
Complejo Hospitalario de Albacete, Albacete, Spain
🇪🇸
Hospital Infanta Cristina,, Badajoz, Spain
🇪🇸
Hospital universitario Virgen de las Nieves, Granada, Spain

and more 15 locations

Levoﬂoxacin and Bismuth-containing Therapy Versus Quadruple Therapy as Second-line Treatment of Resistant Helicobacter Pylori Infection

Phase 4

Completed

Conditions: Cure Rate of Helicobacter Pylori Infection

Interventions: Drug: Proton pump inhibitor
Drug: Bismuth subsalicylate
Drug: Amoxicillin
Drug: Metronidazole
Drug: Levofloxacin
Drug: Tetracycline

First Posted Date: 2012-12-05

Last Posted Date: 2014-08-29

Lead Sponsor: Shanghai Jiao Tong University School of Medicine

Target Recruit Count: 200

Registration Number: NCT01742429

Locations: 🇨🇳
Renji Hospital, Shanghai Jiao-Tong University School of Medicine, Shanghai, Shanghai, China

Study to Evaluate the Efficacy and Safety of Oral Administration With Nemonoxacin and Levofloxacin in Patients With CAP

Phase 3

Completed

Conditions: Pneumonia

Interventions: Drug: Nemonoxacin
Drug: Levofloxacin

First Posted Date: 2012-02-08

Last Posted Date: 2013-06-18

Lead Sponsor: TaiGen Biotechnology Co., Ltd.

Target Recruit Count: 540

Registration Number: NCT01529476

Locations: 🇨🇳
Beijing Union Medical College Hospital, Beijing, China
🇨🇳
China Medical University Hospital, Taichung, Taiwan
🇨🇳
Anzhen Hospital,Beijing Capital Medical University, Anzhen, China

and more 54 locations